{"filing":{"accession_number":"0001193125-26-296710","cik":"0000875320","ticker":"VRTX","company_name":"VERTEX PHARMACEUTICALS INC / MA","form":"8-K","filing_date":"2026-07-06","report_date":null,"primary_document":"d113650d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/875320/000119312526296710/d113650d8k.htm"},"events":[{"id":16287,"run_id":14537,"accession_number":"0001193125-26-296710","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"summary":"Vertex Pharmaceuticals entered into a definitive merger agreement on July 6, 2026, to acquire Crinetics Pharmaceuticals for $85 per share in cash, representing a $10 billion total transaction ($8.8 billion net of cash). The acquisition is expected to be transformative, adding endocrinology assets including PALSONIFY and atumelnant to Vertex's pipeline, with $5 billion+ peak sales opportunity and accretion to non-GAAP operating income by 2029.","company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","filing_date":"2026-07-06","form":"8-K","submitted_at":null,"items":[{"id":14343,"accession_number":"0001193125-26-296710","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Vertex Pharmaceuticals entered into a definitive merger agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash ($10 billion total, $8.8 billion net of cash). The agreement was signed on July 6, 2026, and contemplates a merger with Crinetics surviving as a wholly owned subsidiary of Vertex. This is a material acquisition transaction disclosed under Item 1.01, with clear strategic rationale (endocrinology assets including PALSONIFY and atumelnant), financing arrangements ($4.5 billion bridge facility), and closing conditions including stockholder approval and regulatory clearances.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:06:23.970561+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14344,"accession_number":"0001193125-26-296710","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Vertex Pharmaceuticals announced the acquisition of Crinetics Pharmaceuticals for $85 per share in cash ($10 billion total, $8.8 billion net of cash), unanimously approved by both boards. The investor presentation discloses the transaction structure, strategic rationale, and target company assets (PALSONIFY and atumelnant pipeline), which are hallmarks of material M\u0026A activity under Item 1.01 or 2.01. This is a transformative acquisition expected to accelerate revenue growth and enhance earnings, making it material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:06:23.970561+00:00","company_name":"","ticker":null,"filing_date":""},{"id":14345,"accession_number":"0001193125-26-296710","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The Item 8.01 disclosure announces the execution of a Merger Agreement between Vertex Pharmaceuticals and Crinetics Pharmaceuticals on July 6, 2026, with Vertex acquiring Crinetics for $85 per share in cash ($10 billion total, $8.8 billion net of cash). This is a material acquisition transaction that would substantially affect the registrant's business, financial position, and strategic direction. The supporting exhibits detail the strategic rationale, target company assets (PALSONIFY, atumelnant), and expected financial impact including $5 billion+ peak sales opportunity and accretion to non-GAAP operating income by 2029.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:06:23.970561+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":14343,"accession_number":"0001193125-26-296710","item_number":"1.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.99,"reasoning":"Vertex Pharmaceuticals entered into a definitive merger agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash ($10 billion total, $8.8 billion net of cash). The agreement was signed on July 6, 2026, and contemplates a merger with Crinetics surviving as a wholly owned subsidiary of Vertex. This is a material acquisition transaction disclosed under Item 1.01, with clear strategic rationale (endocrinology assets including PALSONIFY and atumelnant), financing arrangements ($4.5 billion bridge facility), and closing conditions including stockholder approval and regulatory clearances.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:06:23.970561+00:00","company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","filing_date":"2026-07-06"},{"id":14344,"accession_number":"0001193125-26-296710","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.95,"reasoning":"Vertex Pharmaceuticals announced the acquisition of Crinetics Pharmaceuticals for $85 per share in cash ($10 billion total, $8.8 billion net of cash), unanimously approved by both boards. The investor presentation discloses the transaction structure, strategic rationale, and target company assets (PALSONIFY and atumelnant pipeline), which are hallmarks of material M\u0026A activity under Item 1.01 or 2.01. This is a transformative acquisition expected to accelerate revenue growth and enhance earnings, making it material to investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:06:23.970561+00:00","company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","filing_date":"2026-07-06"},{"id":14345,"accession_number":"0001193125-26-296710","item_number":"8.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"The Item 8.01 disclosure announces the execution of a Merger Agreement between Vertex Pharmaceuticals and Crinetics Pharmaceuticals on July 6, 2026, with Vertex acquiring Crinetics for $85 per share in cash ($10 billion total, $8.8 billion net of cash). This is a material acquisition transaction that would substantially affect the registrant's business, financial position, and strategic direction. The supporting exhibits detail the strategic rationale, target company assets (PALSONIFY, atumelnant), and expected financial impact including $5 billion+ peak sales opportunity and accretion to non-GAAP operating income by 2029.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-07T19:06:23.970561+00:00","company_name":"VERTEX PHARMACEUTICALS INC / MA","ticker":"VRTX","filing_date":"2026-07-06"}]}